MDM2 Monoclonal Antibody (IF2) | Invitrogen MA1-113 product information

product summary

company name :

Invitrogen

other brands :

NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience

product type :

antibody

product name :

MDM2 Monoclonal Antibody (IF2)

catalog :

MA1-113

quantity :

100 µg

price :

US 620.00

clonality :

monoclonal

host :

mouse

conjugate :

nonconjugated

clone name :

IF2

reactivity :

human

application :

western blot, immunohistochemistry, immunocytochemistry, immunoprecipitation, immunohistochemistry - paraffin section, immunohistochemistry - frozen section, RNA immunoprecipitation

more info or order :

Invitrogen product webpage

citations: 25

Published Application/Species/Sample/Dilution	Reference
immunohistochemistry; human	SaÃ¢da Bouzid E, Burel Vandenbos F, RanchÃ¨re Vince D, Birtwisle Peyrottes I, Chetaille B, Bouvier C, et al. Prognostic value of HMGA2, CDK4, and JUN amplification in well-differentiated and dedifferentiated liposarcomas. Mod Pathol. 2015;28:1404-14 pubmed publisher
immunohistochemistry - paraffin section; human; 1:50	Weingertner N, Neuville A, Chibon F, Ray Coquard I, Marcellin L, Ghnassia J. Myxoid liposarcoma with heterologous components: dedifferentiation or metaplasia? A FISH-documented and CGH-documented case report. Appl Immunohistochem Mol Morphol. 2015;23:230-5 pubmed publisher
immunohistochemistry - paraffin section; human; 1:50	Righi A, Gambarotti M, Benini S, Gamberi G, Cocchi S, Picci P, et al. MDM2 and CDK4 expression in periosteal osteosarcoma. Hum Pathol. 2015;46:549-53 pubmed publisher
immunohistochemistry - paraffin section; human; 1:100	Ortega P, Suster D, Falconieri G, Zambrano E, Moran C, Morrison C, et al. Liposarcomas of the posterior mediastinum: clinicopathologic study of 18 cases. Mod Pathol. 2015;28:721-31 pubmed publisher
immunohistochemistry - paraffin section; human; 1:100	Yakkioui Y, Temel Y, Creytens D, Jahanshahi A, Fleischeuer R, Santegoeds R, et al. A comparison of cell-cycle markers in skull base and sacral chordomas. World Neurosurg. 2014;82:e311-8 pubmed publisher
immunohistochemistry - paraffin section; human; 1:100; tbl 1.	Yoshida A, Ushiku T, Motoi T, Beppu Y, Fukayama M, Tsuda H, et al. MDM2 and CDK4 immunohistochemical coexpression in high-grade osteosarcoma: correlation with a dedifferentiated subtype. Am J Surg Pathol. 2012;36:423-31 pubmed publisher
immunohistochemistry; human; 1:25; fig 6	Dujardin F, Binh M, Bouvier C, Gomez Brouchet A, Larousserie F, Muret A, et al. MDM2 and CDK4 immunohistochemistry is a valuable tool in the differential diagnosis of low-grade osteosarcomas and other primary fibro-osseous lesions of the bone. Mod Pathol. 2011;24:624-37 pubmed publisher
immunohistochemistry - paraffin section; human; 1:100; fig 2	Yoshida A, Ushiku T, Motoi T, Shibata T, Fukayama M, Tsuda H. Well-differentiated liposarcoma with low-grade osteosarcomatous component: an underrecognized variant. Am J Surg Pathol. 2010;34:1361-6 pubmed publisher
immunohistochemistry - paraffin section; human; 1:100; fig 4	Yoshida A, Ushiku T, Motoi T, Shibata T, Beppu Y, Fukayama M, et al. Immunohistochemical analysis of MDM2 and CDK4 distinguishes low-grade osteosarcoma from benign mimics. Mod Pathol. 2010;23:1279-88 pubmed publisher
immunohistochemistry - paraffin section; human; 1:100	Horvai A, Devries S, Roy R, O Donnell R, Waldman F. Similarity in genetic alterations between paired well-differentiated and dedifferentiated components of dedifferentiated liposarcoma. Mod Pathol. 2009;22:1477-88 pubmed publisher
immunohistochemistry - paraffin section; human; 1:50; fig 1	Daugaard S, Christensen L, Høgdall E. Markers aiding the diagnosis of chondroid tumors: an immunohistochemical study including osteonectin, bcl-2, cox-2, actin, calponin, D2-40 (podoplanin), mdm-2, CD117 (c-kit), and YKL-40. APMIS. 2009;117:518-25 pubmed publisher
immunohistochemistry; human; fig 2	Nahal A, Meterissian S. Lipoleiomyosarcoma of the rectosigmoid colon: a unique site for a rare variant of liposarcoma. Am J Clin Oncol. 2009;32:353-5 pubmed publisher
immunohistochemistry; human; fig 2	Amiot A, Dokmak S, Sauvanet A, Vilgrain V, Bringuier P, Scoazec J, et al. Sporadic desmoid tumor. An exceptional cause of cystic pancreatic lesion. JOP. 2008;9:339-45 pubmed
immunohistochemistry - paraffin section; human; 1:100	Horvai A, Schaefer J, Nakakura E, O Donnell R. Immunostaining for peroxisome proliferator gamma distinguishes dedifferentiated liposarcoma from other retroperitoneal sarcomas. Mod Pathol. 2008;21:517-24 pubmed publisher
immunohistochemistry - paraffin section; human; 1:100; tbl 1	Bosco M, Allia E, Coindre J, Odasso C, Pagani A, Pacchioni D. alpha-fetoprotein expression in a dedifferentiated liposarcoma. Virchows Arch. 2006;448:517-20 pubmed
immunohistochemistry - paraffin section; human; 1:200; tbl 1	Mentzel T, Toennissen J, Rutten A, Schaller J. Palmar atypical lipomatous tumour with spindle cell features (well-differentiated spindle cell liposarcoma): a rare neoplasm arising in an unusual anatomical location. Virchows Arch. 2005;446:300-4 pubmed
immunohistochemistry - frozen section; human; 1:100; fig 3	Coindre J, Hostein I, Maire G, Derré J, Guillou L, Leroux A, et al. Inflammatory malignant fibrous histiocytomas and dedifferentiated liposarcomas: histological review, genomic profile, and MDM2 and CDK4 status favour a single entity. J Pathol. 2004;203:822-30 pubmed
immunohistochemistry - paraffin section; human	Coindre J, Mariani O, Chibon F, Mairal A, De Saint Aubain Somerhausen N, Favre Guillevin E, et al. Most malignant fibrous histiocytomas developed in the retroperitoneum are dedifferentiated liposarcomas: a review of 25 cases initially diagnosed as malignant fibrous histiocytoma. Mod Pathol. 2003;16:256-62 pubmed
	García Carpio I, Braun V, Weiler E, Leone M, Ni xf1 erola S, Barco A, et al. Extra centrosomes induce PIDD1-mediated inflammation and immunosurveillance. EMBO J. 2023;:e113510 pubmed publisher
	Mozūraitienė J, Gudleviciene Z, Vincerzevskiene I, Laurinaviciene A, Pamedys J. Expression levels of FBXW7 and MDM2 E3 ubiquitin ligases and their c-Myc and p53 substrates in patients with dysplastic nevi or melanoma. Oncol Lett. 2021;21:37 pubmed publisher
	Sladky V, Knapp K, Szabó T, Braun V, Bongiovanni L, van den Bos H, et al. PIDDosome-induced p53-dependent ploidy restriction facilitates hepatocarcinogenesis. EMBO Rep. 2020;21:e50893 pubmed publisher
	Muller I, Strozyk E, Schindler S, Beissert S, Oo H, Sauter T, et al. Cancer Cells Employ Nuclear Caspase-8 to Overcome the p53-Dependent G2/M Checkpoint through Cleavage of USP28. Mol Cell. 2020;77:970-984.e7 pubmed publisher
	Casadei L, Calore F, Braggio D, Zewdu A, Deshmukh A, Fadda P, et al. MDM2 Derived from Dedifferentiated Liposarcoma Extracellular Vesicles Induces MMP2 Production from Preadipocytes. Cancer Res. 2019;79:4911-4922 pubmed publisher
	Payton M, Cheung H, Ninniri M, Marinaccio C, Wayne W, Hanestad K, et al. Dual Targeting of Aurora Kinases with AMG 900 Exhibits Potent Preclinical Activity Against Acute Myeloid Leukemia with Distinct Post-Mitotic Outcomes. Mol Cancer Ther. 2018;17:2575-2585 pubmed publisher
	Helbig D, Ihle M, PÃ¼tz K, Tantcheva Poor I, Mauch C, BÃ¼ttner R, et al. Oncogene and therapeutic target analyses in atypical fibroxanthomas and pleomorphic dermal sarcomas. Oncotarget. 2016;7:21763-74 pubmed publisher

image

image 1 :

Immunofluorescent analysis of MDM2 (green) in HeLa cells either left untreated (left panel) or treated with 50nM Nocodazole (right panel) for 16 hours. Formalin fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 10 minutes at room temperature and blocked with 1% Blocker BSA (Product # 37525) for 15 minutes at room temperature. Cells were probed with a MDM2 monoclonal antibody (Product # MA1-113) at a concentration of 1ug/ml for at least 1 hour at room temperature, washed with PBS, and incubated with DyLight 488 goat anti-mouse IgG secondary antibody (Product # 35502) at a dilution of 1:400 for 30 minutes at room temperature. F-Actin (red) was stained with DyLight 554 Phalloidin (Product # 21834) and nuclei (blue) were stained with Hoechst 33342 dye (Product # 62249). Images were taken on a Thermo Scientific ArrayScan or ToxInsight Instrument at 20X magnification.

product information

Product Type :

Antibody

Product Name :

MDM2 Monoclonal Antibody (IF2)

Catalog # :

MA1-113

Quantity :

100 µg

Price :

US 620.00

Clonality :

Monoclonal

Purity :

protein A

Host :

Mouse

Reactivity :

Human

Applications :

Immunocytochemistry: 1-5 µg/mL, Immunohistochemistry (Frozen): 1-5 µg/mL, Immunohistochemistry (Paraffin): 1:10-1:500, Immunoprecipitation: 1-5 µg/mL, RNA Immunoprecipitation: Assay-dependent, Western Blot: 0.5-2 µg/mL

Species :

Human

Clone :

IF2

Isotype :

IgG2b

Storage :

-20° C, Avoid Freeze/Thaw Cycles

Description :

MDM2 is a ubiquitin ligase for p53 and plays a central role in regulation of the stability of p53. MDM2 is located on chromosome 12 on the q arm. Akt-mediated phosphorylation of MDM2 at Ser166 and Ser186 increases its interaction with p300, allowing MDM2-mediated ubiquitination and degradation of p53. Phosphorylation of MDM2 also blocks its binding to p19ARF, increasing the degradation of p53. MDM2 has also been shown to negatively regulate p53 function. MDM2 binds and inhibits transactivation role played by p53 and overexpression of MDM2 can result in the inactivation of p53 and decrease its tumor suppressor function. Another process by which MDM2 can inactivate p53 is by degrading p53 as the protein also possesses E3 ubiquitin ligase activity. Further, MDM2 plays important roles in apoptosis and cell cycle. MDM2 is over expressed in a wide range of human malignancies including soft tissue carcinomas and breast cancer. In addition to p53, MDM2 is involved in processes of cell cycle, apoptosis, and tumorigenesis through interactions with proteins that include retinoblastoma 1 and ribosomal protein L5. More than 40 different alternatively spliced transcript variants of MDM2 have been isolated from both tumor and normal tissues.

Immunogen :

Human MDM2

Format :

Liquid

Applications w/Dilutions :

Aliases :

1700007J15Rik; AA415488; ACTFS; double minute 2; double minute 2 protein; double minute 2, human homolog of; p53-binding protein; E3 ubiquitin-protein ligase Mdm2; Hdm2; HDMX; HGNC:6973; human homolog of; MDM2; Mdm-2; MDM2 oncogene, E3 ubiquitin protein ligase; Mdm2 p53 binding protein homolog; MDM2 proto-oncogene; MDM2 proto-oncogene, E3 ubiquitin protein ligase; MDM2 variant FB28; Mdm2, p53 E3 ubiquitin protein ligase homolog; Mdm2, transformed 3T3 cell double minute 2, p53 binding protein; MGC5370; MGC71221; oncoprotein Mdm2; OTTHUMP00000183490; OTTHUMP00000183492; OTTHUMP00000183494; OTTHUMP00000183495; OTTHUMP00000183496; OTTHUMP00000183497; p53 E3 ubiquitin protein ligase; p53-binding protein Mdm2; RING-type E3 ubiquitin transferase Mdm2; transformed mouse 3T3 cell double minute 2

more info or order :

Invitrogen product webpage